The outcome of intensive induction therapy in patients ≥70 years with acute myeloid leukemia [10]

Leukemia

Volumn 21, Issue 6, 2007, Pages 1321-1324

  Gupta, V ^a   Xu, W ^a   Keng, C ^a   Alibhai, S M H ^b   Brandwein, J ^a   Schimmer, A ^a   Schuh, A ^a   Yee, K ^a   Minden, M D ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; AGE DISTRIBUTION; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; CYTOGENETICS; DRUG MEGADOSE; ELDERLY CARE; FEMALE; FUNCTIONAL ASSESSMENT; HIGH RISK PATIENT; HUMAN; LETTER; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 34249713797     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404655     Document Type: Letter

References (8)

1. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: The results of the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1302-1311.
2. Anderson JE, Kopecky KJ, Willman CL, Head D, O'Donnell MR, Luthardt FW et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: A Southwest Oncology Group study. Blood 2002; 100: 3869-3876.
3. Lowenberg B, Suciu S, Archimbaud E, Ossenkoppele G, Verhoef GE, Vellenga E et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: Final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood 1997; 90: 2952-2961.
4. Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, Caligiuri MA et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002; 100: 1224-1232.
5. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman RP et al. Postremission therapy in older patients with de novo acute myeloid leukemia: A randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 2001; 98: 548-553.
6. Gupta V, Chun K, Yi QL, Minden M, Schuh A, Wells R et al. Disease biology rather than age is the most important determinant of survival of patients > or =60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer 2005; 103: 2082-2090.
7. Frohling S, Schlenk RF, Kayser S, Morhardt M, Benner A, Dohner K et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 2006; 108: 3280-3288.
8. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481-3485.